Global Investor Forum Contact

Werners Verbiest

Global Head, Janssen Diagnostics

Session

11:30 - 12:45
From general to personalized

Track leader

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Abstract

Aiming High for Precision Medicine – A World Without Disease
Precision medicine’s greatest value may derive from shifting our unprecedented tools and technologies from the back end of diseases (treating diseases and their systems) to their front end: pre-disease interception and disease prevention.
Janssen Diagnostics’ vision of precision medicine goes beyond merely prescribing the right medicine to the right patient; it includes disease prevention, interception and cure. We envision a new era in healthcare, centered on precise medical interventions based on a person’s unique physiology and disease susceptibility, a future where disease interception and prevention is the norm. In order to achieve this, we need to tear down the barriers and silos between the players of healthcare industry and also embrace/integrate new players into the system and integrated solutions.

Kees Been
Lysosomal Therapeutics Inc.

Erik van de Berg
AM-Pharma

René Bernards
Qameleon Therapeutics & NKI

Annelien Bredenoord
UMC Utrecht

Carine van den Brink
AXON Lawyers

Danielle Curfs
Chemelot InSciTe
Jenny Dankelman
TU Delft
Diederik Dippel
Erasmus MC

Cornelia van Duijn
Erasmus MC

Lude Franke
UMCG
Thibault Helleputte
DNAlytics
Mark van Houdenhoven
St. Maartenskliniek
Henk Joos
Flanders Bio
Peter de Keizer
Erasmus MC
Tim Knotnerus
AM-Pharma, PRIMER Professionals
Angus Livingstone
Oncode Institute
Travis McCready
Massachusetts Life Sciences Center

Mirjam Mol
Pivot Park

Barend Mons
DTL & LUMC
Timothy Noël
Eindhoven University of Technology
Jacquelien Noordhoek
Dutch CF Foundation
Violet Petit-Steeghs
Athena Institute
Thomas Plochg
NPHF
Dirk Jan van der Pol
Ordina
Anne Portwich
LSP
Elisabeth van Rossum
Erasmus MC
André van de Sande
Xendo
Marlies Schijven
AMC
Hans Schikan
Topsector LSH
Hanneke Schuitemaker
Janssen Vaccines
Frits Schut
V.O. Patents & Trademarks
Marieke Schuurmans
UMC Utrecht
Jacob Seidell
VU
Agaath Sluijter
Medical Delta
Thijs Spigt
Erasmus MC
Marianne van der Steen
Maastricht University
Maarten Steinbuch
Eindhoven University of Technology
Onno van de Stolpe
Galapagos
Werner Verbiest
Janssen Diagnostics
Martine de Vries
LUMC

Edward van Wezel
BioGeneration Ventures

Jan van de Winkel
Genmab

Loek Winter
DC Klinieken

Hanneke Heeres
Health~Holland
Caroline Duterloo
Medical Delta
Paul Korte
Janssen
Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2017 Innovation for Health